Alzheimer’s Blood Biomarkers Linked to Early Cognitive Decline, Study Shows

Testing for Alzheimer’s disease through blood biomarkers may identify cognitive decline years before symptoms emerge, according to a study published in The Lancet in 2023. Researchers at the University of California, San Francisco (UCSF) found that elevated levels of tau and amyloid proteins in blood correlated with lower baseline cognitive performance and faster memory deterioration in middle-aged adults without dementia.

How Do Blood Biomarkers Correlate with Cognitive Decline?

A study involving 1,350 participants aged 53 to 69 from the Coronary Artery Risk Development in Young Adults (CARDIA) study revealed that 6% had high levels of Alzheimer’s-related biomarkers. These individuals scored lower on tests measuring processing speed and executive function at the study’s outset. Five years later, they faced a 2.5 to 4 times higher risk of rapid verbal memory decline and a 3 to 4 times greater risk of worsening processing speed, according to the research.

“The pathology of Alzheimer’s begins years before symptoms appear,” said Dr. Kristine Yaffe, a UCSF psychiatry professor. “Identifying these biomarkers could help patients address modifiable risk factors and seek early intervention.”

What Makes Blood Tests a Viable Alternative to Traditional Methods?

Unlike brain imaging or cerebrospinal fluid tests, blood analyses are non-invasive and cost-effective. However, the study emphasized the need for caution. The biomarkers specifically indicate Alzheimer’s pathology, not other dementia types, and false positives remain a concern. “These tests are not a standalone diagnostic tool,” Yaffe noted. “They should be used alongside clinical evaluation.”

Why Does This Matter for Early Detection Efforts?

Alzheimer’s affects 60-70% of dementia cases, making early detection critical. The study’s findings align with growing evidence that biomarkers could enable earlier intervention. For example, a 2022 JAMA Neurology study found similar associations between blood amyloid levels and cognitive decline, though with smaller sample sizes.

Researchers stressed that while the results are promising, larger, longitudinal studies are needed to confirm long-term predictive value. The CARDIA cohort’s diverse demographics—58% women, 45% Black participants—also highlight the importance of validating these findings across racial and gender groups.

What Are the Next Steps for Patients and Clinicians?

Experts caution against overreliance on blood tests for diagnosis. “These results suggest a potential tool, but they’re not a replacement for comprehensive assessment,” said Dr. Mary Sano, a neurologist at the Alzheimer’s Association. Patients with elevated biomarkers should consult specialists to explore lifestyle changes, clinical trials, or other interventions.

The study underscores the need for public health strategies targeting midlife risk factors. “If we can intervene earlier, we may delay or prevent cognitive decline,” Yaffe said. “This is a step toward personalized dementia prevention.”